Business
Annovis Bio is a late-stage clinical drug platform company developing buntanetap for neurodegenerative diseases including Alzheimer's disease and Parkinson's disease.
Annovis had zero revenue, the net loss widened to $28.9M, and cash from ops worsened to -$25.6M.
The read at a glance✓ Audited against SEC data
- Business mix — Neurodegeneration drug platformNote
- Revenue — Revenue was $0Note
- Profitability — Net loss widened 17.3%Watch
- Cash — Cash from ops was -$25.6MWatch
- Balance sheet — Equity rose 81.0%OK
- Insiders — 7 buys / 0 sellsOK
- Accounting — Latest Altman-Z distressWatch
Leadership changes
From Annovis Bio, Inc.'s own filings, the day they're filed.
- Mark Guerin · Chief Financial Officer · departureeff. 2026-03-23
- Mark Guerin · Chief Financial Officer · appointmenteff. 2025-09-25
- Andrew Walsh · President · departureeff. 2025-08-22
Latest filings
- 10-Q · Quarterly report2026-08-14
- 8-K · Company announcement2026-08-14
- 8-K · Company announcement2026-07-10
- 8-K · Company announcement2026-06-17
- 8-K · Company announcement2026-05-20
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Annovis Bio, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.